The company said it had engaged TRPL (Transdermal Research Pharm Laboratories) of Long Island City, New York, to conduct a feasibility study — which indicates that HCQ has all the required parameters to be a transdermal candidate.
Moreover, in recognition of the potential value of this legacy asset and in light of the company’s current focus on the blockchain and related emerging technology ecosystem, Codebase said it is investigating spinning out its interest in the transdermal delivery technology for HCQ.
Codebase said details on any such spin-out will be provided in the coming weeks as it explores deal structures with its partners to ensure its shareholders benefit.
Codebase noted that it has a 49% interest in Glanis Pharmaceuticals Inc, an arms-length private company that holds provisional US patents for transdermal and oral mucosal delivery of hydroxychloroquine and chloroquine (CQ). The drug has been approved by the US Food and Drug Administration (FDA) as a treatment against malaria, lupus, and rheumatoid arthritis.
On the basis of positive results from the feasibility study, Codebase said the parties are beginning the process from a provisional to a full patent.
- The market for HCQ forecast to reach $6 billion by 2027 as FDA-approved treatment for malaria, lupus, and rheumatoid arthritis;
- Codebase receives positive technical feasibility study results indicating HCQ has all the required parameters to be delivered transdermally; and
- HCQ transdermal treatment for malaria, lupus, and rheumatoid arthritis patients likely to resolve oral tablet side effects as it would bypass the first-pass metabolism.
Meanwhile, Codebase said it has received interest in the application of HCQ in a transdermal patch for underserved patients with malaria, lupus, and rheumatoid arthritis, as current oral tablet delivery of HCQ comes with side effects that transdermal delivery is likely to resolve.
Transdermal delivery can provide a drug plasma concentration at a predetermined rate for a predetermined period of time, Codebase said. Safe, consistent doses will make the drug much more effective at reduced dosages required because the GI system is avoided.
Codebase said this new delivery method should eliminate or reduce the number of the common side effects of the oral tablet treatment, including nausea, vomiting, loss of appetite, diarrhea, dizziness, or headache, by providing controlled constant delivery.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham
Story by ProactiveInvestors
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 888-809-8385 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
pathogens and gives you more
energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video)
Immusist Beverage Concentrate - Proprietary blend, formulated to reduce inflammation while hydrating and oxygenating the cells.